Nacimbio JSC, a pharmaceutical holding company of Rostec Corporation, received the status of sole supplier of immunobiological medicines used for vaccinations under the National Vaccination Schedule.
In 2018-2019, the company will supply to the Ministry of Health the vaccines manufactured at all stages of technological process within Russia.
“Our reliability as the sole supplier is confirmed by previous years of successful work with the Ministry of Health. We are ready for further collaboration and, to this end, we are not only improving the competencies in the area of logistics, but also facilitate the transfer of required technologies and full cycle manufacturing of immunobiological products in Russia,” said Andrey Zagorskiy, the General Manager of the holding company.
In Russia, 89 million people, including 30 million children, are vaccinated every year under the National Vaccination Schedule.
In 2015-2017, Nacimbio supplied nearly 260 million doses of vaccines for public health institutions. More than half of these supplies was the flue vaccine. Last year, as the sole supplier, the holding company contributed to unprecedented expansion in the coverage of population by preventive flu vaccination (almost 47% of Russia’s total population). In addition, given the government’s objectives to further develop National Vaccination Schedule, the company is designing new combination vaccines to reduce the injection burden, primarily, in pediatric practice.